ES2156997T3 - Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1). - Google Patents

Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1).

Info

Publication number
ES2156997T3
ES2156997T3 ES96924553T ES96924553T ES2156997T3 ES 2156997 T3 ES2156997 T3 ES 2156997T3 ES 96924553 T ES96924553 T ES 96924553T ES 96924553 T ES96924553 T ES 96924553T ES 2156997 T3 ES2156997 T3 ES 2156997T3
Authority
ES
Spain
Prior art keywords
acid
heptanoico
calcica
fluorophenil
amorfo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96924553T
Other languages
English (en)
Spanish (es)
Inventor
Min Lin
Dieter Schweiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2156997T3 publication Critical patent/ES2156997T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
ES96924553T 1995-07-17 1996-07-16 Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1). Expired - Lifetime ES2156997T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
ES2156997T3 true ES2156997T3 (es) 2001-08-01

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96924553T Expired - Lifetime ES2156997T3 (es) 1995-07-17 1996-07-16 Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1).

Country Status (37)

Country Link
US (1) US6274740B1 (OSRAM)
EP (1) EP0839132B1 (OSRAM)
JP (1) JP4064459B2 (OSRAM)
KR (1) KR100400805B1 (OSRAM)
CN (1) CN1087289C (OSRAM)
AR (1) AR002849A1 (OSRAM)
AT (1) ATE199542T1 (OSRAM)
AU (1) AU700794B2 (OSRAM)
BG (1) BG63631B1 (OSRAM)
BR (1) BR9609714A (OSRAM)
CA (1) CA2220455C (OSRAM)
CO (1) CO4700441A1 (OSRAM)
CZ (1) CZ289421B6 (OSRAM)
DE (1) DE69611999T2 (OSRAM)
DK (1) DK0839132T5 (OSRAM)
EA (1) EA000625B1 (OSRAM)
EE (1) EE03605B1 (OSRAM)
ES (1) ES2156997T3 (OSRAM)
GE (1) GEP20002027B (OSRAM)
GR (1) GR3035859T3 (OSRAM)
HR (1) HRP960312B1 (OSRAM)
HU (1) HU220343B (OSRAM)
IL (1) IL122161A (OSRAM)
IN (1) IN185276B (OSRAM)
MX (1) MX9708959A (OSRAM)
NO (1) NO309322B1 (OSRAM)
NZ (1) NZ313008A (OSRAM)
PE (1) PE1698A1 (OSRAM)
PL (1) PL191017B1 (OSRAM)
PT (1) PT839132E (OSRAM)
RO (1) RO120069B1 (OSRAM)
SI (1) SI0839132T1 (OSRAM)
SK (1) SK283204B6 (OSRAM)
UA (1) UA50743C2 (OSRAM)
UY (1) UY24286A1 (OSRAM)
WO (1) WO1997003960A1 (OSRAM)
ZA (1) ZA966043B (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (OSRAM) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CN1330644C (zh) * 2000-11-16 2007-08-08 特瓦制药工业有限公司 用氢氧化钙水解[R(R*,R*)]－2－(4－氟代苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸酯
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ES2319870T3 (es) 2000-12-27 2009-05-14 Teva Pharmaceutical Industries Limited Formas cristalinas de atorvastatina.
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (OSRAM) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
AP1571A (en) * 2001-06-29 2006-02-10 Warner Lambert Co Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ATE452871T1 (de) * 2002-03-18 2010-01-15 Biocon Ltd Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
AU2003231926A1 (en) 2003-04-22 2004-11-19 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ss-KETOESTERS
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7557238B2 (en) 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
CA2560252C (en) * 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008510798A (ja) 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
DE05810535T1 (de) * 2004-10-18 2007-04-19 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von amorphem atorvastatin-hemi-calcium durch lösen des salzes in einem organischen lösungsmittel, bei dem es sich um eine mischung enes alkohols und eines ketons und/oder eines esters handelt, und entfernen des lösungsmittels
WO2006046109A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
EP1814541A4 (en) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20070249845A1 (en) * 2006-03-01 2007-10-25 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
KR100389518B1 (ko) 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)

Also Published As

Publication number Publication date
DE69611999D1 (de) 2001-04-12
AU700794B2 (en) 1999-01-14
IL122161A0 (en) 1998-04-05
AU6497896A (en) 1997-02-18
SI0839132T1 (OSRAM) 2001-06-30
ZA966043B (en) 1997-02-03
NO309322B1 (no) 2001-01-15
BG63631B1 (bg) 2002-07-31
GR3035859T3 (en) 2001-08-31
EP0839132B1 (en) 2001-03-07
RO120069B1 (ro) 2005-08-30
SK5898A3 (en) 1998-08-05
US6274740B1 (en) 2001-08-14
PL191017B1 (pl) 2006-03-31
ATE199542T1 (de) 2001-03-15
HRP960312A2 (en) 1998-02-28
IL122161A (en) 1999-07-14
HUP9903017A3 (en) 2001-01-29
KR100400805B1 (ko) 2003-12-24
UY24286A1 (es) 1997-01-17
NO980209L (no) 1998-01-16
PE1698A1 (es) 1998-02-19
EE9700369A (et) 1998-06-15
SK283204B6 (sk) 2003-03-04
IN185276B (OSRAM) 2000-12-16
DE69611999T2 (de) 2001-07-26
CA2220455A1 (en) 1997-02-06
EP0839132A1 (en) 1998-05-06
JPH11510486A (ja) 1999-09-14
HU220343B (hu) 2001-12-28
HK1018054A1 (en) 1999-12-10
DK0839132T5 (da) 2006-03-20
WO1997003960A1 (en) 1997-02-06
GEP20002027B (en) 2000-04-10
CA2220455C (en) 2002-09-24
EE03605B1 (et) 2002-02-15
DK0839132T3 (da) 2001-04-09
EA199800128A1 (ru) 1998-08-27
BR9609714A (pt) 1999-02-23
EA000625B1 (ru) 1999-12-29
PL324463A1 (en) 1998-05-25
CZ289421B6 (cs) 2002-01-16
CN1087289C (zh) 2002-07-10
MX9708959A (es) 1998-03-31
NO980209D0 (no) 1998-01-16
CN1190956A (zh) 1998-08-19
HRP960312B1 (en) 2001-10-31
NZ313008A (en) 2000-01-28
CO4700441A1 (es) 1998-12-29
CZ12298A3 (cs) 1998-12-16
BG102188A (en) 1998-08-31
PT839132E (pt) 2001-06-29
AR002849A1 (es) 1998-04-29
JP4064459B2 (ja) 2008-03-19
UA50743C2 (uk) 2002-11-15
KR19990029045A (ko) 1999-04-15

Similar Documents

Publication Publication Date Title
ES2156997T3 (es) Proceso nuevo para la produccion de sal calcica del acido amorfo (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (2:1).
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
EE200200293A (et) Meetod amorfse atorvastatiini valmistamiseks
ES2167306T3 (es) Acido (r-(r*,r*))-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4((fenilamino)-carbonil)-1h-pirrol-1-heptanoico, su forma de lactona y sales derivadas.
RU95114376A (ru) Нитроэфиры, обладающие фармакологической активностью, и способ их получения
AU8772691A (en) New compounds
UY24285A1 (es) Procedimiento para la preparación de ácido cristalino
CA2058328A1 (en) 2-aryl-5-trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
RU94045268A (ru) Способ получения 1-(алкоксиметил)пиррольных соединений
NZ511503A (en) Manufacture of clevidipine by reacting an inorganic salt of a carboxylic acid with choromethyl butyrate
EA199800280A1 (ru) Новые производные 5-0-дезозаминил-6-0-метилэритронолида а, способ их получения и их использование при получении биологически активных продуктов
AR002306A1 (es) Procedimiento mejorado para la preparacion de una sal de 5-(alcoximetil)piridina-2,3-dicarboxilato
PT98477A (pt) Processo para a preparacao de compostos 2-aril-5-(trifluorometil)pirrole uteis como insecticidas acaricidas e nematicidas
ES2157232T3 (es) Procedimiento para la preparacion de 2,4,5-tribromo-pirrol-3-carbonitrilo.
ID16017A (id) Proses yang dimanfaatkan untuk memproduksi asam organik
ECSP961822A (es) NUEVO PROCESO PARA LA PRODUCCION DE UNA SAL ACIDA CALCICA AMORFA [R- (R*, R*)]-2-(4- FLUOROFENILO)-ß, 6- DIHIDROXI- 5 - (1- METILETILO)- 3 - FENILO -4-[(FENILAMINO) CARBONILO] - 1H- PIRROL - 1 - ACIDO HEPTANOICO
MX9704257A (es) Proceso para la preparacion de compuestos de 5-(alcoximetil) -2,3-piridinodicarboximida.
ATE48414T1 (de) Gesaettigte cycloalkyl(b)pyrrol 1(2h)essigs|ureamide und deren derivate.
HUT42083A (en) Herbicides containing azolides of kynolin-8-carbonic acid and process for production of the active substance
EA200200491A1 (ru) Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцины и их применение в качестве лекарственных средств
BR9402825A (pt) Amidas de pirazol carbóxi ácidos, acaracidas e inseticidas, processo para sua produção e composições tendo atividade acaricida e inseticida
ES2011587A6 (es) Procedimiento de obtencion de un derivado de pirrolidona y sus sales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 839132

Country of ref document: ES